In this study, we have determined the limit of protection achievable by immunisation with sub-units of Yersinia pestis against the development of plague in an experimental animal model. Co-immunisation with the purified culture-derived F1 and the recombinant V sub-units afforded a greater level of protection than with either sub-unit alone. The protection given by the combined sub-units was several orders of magnitude greater than that afforded by the whole cell killed (Cutter USP) vaccine and was equivalent to that achieved by vaccination with EV76, the live attenuated Y. pestis vaccine strain. However, the combined sub-unit vaccine has clear advantages over the live vaccine in terms of safety of use and absence of side-effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1574-695X.1995.tb00196.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Improved Sporozoite Seroneutralization Assay for the Identification of East Coast Fever Immune Correlates.
Antibodies (Basel)
December 2024
Animal and Human Health Program, International Livestock Research Institute, Nairobi P.O. Box 30709, Kenya.
Background: Immune correlates of protection are ideal tools to predict treatment or vaccine efficacy. However, the accuracy of the immune correlate and the capability to robustly predict the outcome of a vaccine candidate are determined by the performance of the in vitro immunoassay used. Several sporozoite seroneutralization assays have previously been used to assess antibody functional activities; however, a common limitation has been the need for fresh material, target cells and sporozoites, and operator-to-operator bias.
View Article and Find Full Text PDFImmunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus.
Vaccines (Basel)
August 2024
College of Veterinary Medicine & Institute of Animal Medicine, Gyeongsang National University, Jinju 52828, Gyeongsangnam-do, Republic of Korea.
Nipah virus (NiV), of the Paramyxoviridae family, causes highly fatal infections in humans and is associated with severe neurological and respiratory diseases. Currently, no commercial vaccine is available for human use. Here, eight structure-based mammalian-expressed recombinant proteins harboring the NiV surface proteins, fusion glycoprotein (F), and the major attachment glycoprotein (G) were produced.
View Article and Find Full Text PDFIn silico and in vitro evaluation of the immunogenic potential of Leishmania donovani ascorbate peroxidase and its derived peptides.
Acta Trop
December 2024
Department of Biochemistry, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, 800007, Bihar, India. Electronic address:
The control and eradication of any infectious disease is only possible with a potential vaccine, which has not been accomplished for human visceral leishmaniasis (VL). The lack of vaccines may increase the risk of VL outbreaks periodically in endemic zones. Identifying a reliable vaccine candidate for Leishmania is a major challenge.
View Article and Find Full Text PDFResearch Progress in the Development of Vaccines against Mycoplasma and Mycoplasma .
Microorganisms
August 2024
Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai'an 271018, China.
Article Synopsis
- * There is currently no specific medication for treating mycoplasma diseases in chickens, making vaccination the primary method of control.
- * The paper reviews various vaccine types available for MG and MS, such as live, inactivated, sub-unit, and vector vaccines.
An immunoinformatics approach for design and validation of multi-subunit vaccine against from essential hypothetical proteins.
J Parasit Dis
September 2024
School of Biotechnology, KIIT Deemed to Be University, Bhubaneswar, Odisha 751024 India.
Unlabelled: Malaria, caused by , remains a pressing global health concern. Advancements in combating this parasite involve the development of a protein vaccine. This study employs immunoinformatics to identify potential vaccine candidates within the repertoire of 218 .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!